Clinical research
OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
The Data Safety Monitoring Board ran a safety review and recommended the trials end because of an unfavorable risk-benefit ratio.
Tocagen said the late-stage Toca 5 trial evaluating Toca 511 & Toca FC in patients with recurrent high-grade glioma undergoing resection missed its overall survival endpoint compared to standard of care treatment.
The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures
Pratteln, Switzerland, September 10, 2019 – Santhera Pharmaceuticals announces the online publication of Phase I data with its human neutrophil elastase inhibitor POL6014 in the Journal of Cystic Fibrosis.
The results of the two long-term trials showed that patients receiving the company’s checkpoint inhibitor, Opdivo (nivolumab), had a long-term overall survival improvement compared to docetaxel chemotherapy alone.
Shares of AVEO Oncology are climbing fast in premarket trading after the company released data that showed positive overall survival benefits of tivozanib in patients with highly refractory metastatic renal cell carcinoma who have received prior immunotherapy treatments.
PRESS RELEASES